Researchers in dermatology at Lund University in Sweden believe they have cracked the mystery of why we are able to quickly prevent an infection from spreading uncontrollably in the body during wounding. They believe this knowledge may be of clinical significance for developing new ways to counteract bacteria.
“Perhaps we don’t need to kill them with antibiotics but simply gather them so that the body can better take care of the infection”, say researchers Jitka Petrlova (lead author of the article) and Artur Schmidtchen, Professor in Dermatology and Venereology, Lund University. The study was conducted in close collaboration with their colleagues in Lund, Copenhagen and Singapore, and has been published in the scientific journal Proceedings of the National Academy of Sciences (PNAS).
The researchers have discovered that fragments of thrombin – a common blood protein which can be found in wounds – can aggregate both bacteria and their toxins; something they did not see in normal blood plasma. The aggregation takes place quickly in the wound and causes bacteria and endotoxins not only to gather but also to be “eaten” by the body’s inflammatory cells.
“This way, the body avoids a spread of the infection. We believe this to be a fundamental mechanism for taking care of both bacteria and their toxins during wound healing”, says Jitka Petrlova and continues;
“Our discovery links aggregation and amyloid formation to our primary defence against infections – our innate immunity. It is well known that various aggregating proteins can cause amyloid disease, in skin or internal organs, such as the brain. Therefore, a mechanism that is supposed to protect us from infections, can sometimes be over-activated and lead to degenerative diseases.”
Artur Schmidtchen, who has conducted research in the field of innate immunity for over 20 years, is pleased with the results of the study.
“I have always been fascinated by how nature has effectively created different defence mechanisms, and wound healing provides a rich source of new discoveries. The ability to effectively heal wounds is of evolutionary significance to our survival. Compared to antibiotics, innate immunity has been around for millions of years – and I think we should consider the application of these concepts in an era of increasing antibiotic resistance.”
The Latest on: Innate immunity
The Immune System's Influence on Brain Development Reviewed
on April 18, 2018 at 1:45 am
Research has revealed that deficiency of the innate immune adaptor TRIF, which is essential for certain Toll-like receptor signaling cascades, significantly shortened survival time of ALS mice. The life-saving drug used to treat opioid overdose ... […]
Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting
on April 17, 2018 at 1:24 pm
Sarah McWhirter of Aduro Biotech presented updated preclinical data demonstrating that an optimized dosing regimen of ADU-S100 administered intratumorally activates acute innate immunity as well as adaptive CD8+ T cells necessary and sufficient for ... […]
INNATE PHARMA : Promising anti-tumor activity of monalizumab with cetuximab in SCCHN
on April 17, 2018 at 11:10 am
... cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immunity. Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing ... […]
Vaccines are medicine’s most important invention—but they could be even more effective
on April 17, 2018 at 7:54 am
Before the doctor injected that vaccine into my arm all those years ago, the other pillar, termed the innate immune system, was prepared to respond to invaders. This response is the natural, front-line defense we are born with. If the adaptive immune ... […]
Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
on April 17, 2018 at 6:52 am
CMP-001 is designed to activate innate immunity to convert “uninflamed” tumors, which generally do not respond to anti-PD-1 therapy, into “inflamed” tumors, which are PD-1 responsive. Data were presented in the clinical trials plenary session on ... […]
via Google News and Bing News